Abstract
For many years the mechanisms of intrinsic or acquired drug resistance have been the major object for molecular oncologists and clinicians, because resistance to chemotherapy critically limits the outcome of cancer treatment. Initially, the interaction of a drug with its molecular target that yields a lethal lesion has been studied - at the target level or upstream of this interaction (drug influx and efflux, detoxification, DNA repair etc.). Later, it was discovered that downstream cellular responses to a given DNA lesion can determine the outcome of the therapy, focusing the investigation on the processes of the programmed cell death. More recently a new phenomenon of drug resistance has been discovered, called Cell Adhesion-Mediated Drug Resistance. It is based on the adherence of cells to extracellular matrix proteins through adhesive molecules such as integrins. Integrins are cell surface heterodimeric receptors that mediate cell-extracellular matrix adhesion. They trigger many intracellular signaling pathways involved in a cell proliferation, survival/apoptosis, shape, polarity, motility, and differentiation. Integrins may protect cancer cells from an array of cytotoxic agents in several ways. This review will focus on the role of integrins in conferring resistance to tumor cells. We will discuss specific signal transduction pathways initiated by integrin ligation as a source of potential therapeutic targets for the fight against cancer.
Keywords: Integrin, drug-resistance, survival, cell cycle, apoptosis, tumor cells
Current Signal Transduction Therapy
Title: Integrin-Mediated Drug Resistance
Volume: 1 Issue: 2
Author(s): Andreja Ambriovic-Ristov and Maja Osmak
Affiliation:
Keywords: Integrin, drug-resistance, survival, cell cycle, apoptosis, tumor cells
Abstract: For many years the mechanisms of intrinsic or acquired drug resistance have been the major object for molecular oncologists and clinicians, because resistance to chemotherapy critically limits the outcome of cancer treatment. Initially, the interaction of a drug with its molecular target that yields a lethal lesion has been studied - at the target level or upstream of this interaction (drug influx and efflux, detoxification, DNA repair etc.). Later, it was discovered that downstream cellular responses to a given DNA lesion can determine the outcome of the therapy, focusing the investigation on the processes of the programmed cell death. More recently a new phenomenon of drug resistance has been discovered, called Cell Adhesion-Mediated Drug Resistance. It is based on the adherence of cells to extracellular matrix proteins through adhesive molecules such as integrins. Integrins are cell surface heterodimeric receptors that mediate cell-extracellular matrix adhesion. They trigger many intracellular signaling pathways involved in a cell proliferation, survival/apoptosis, shape, polarity, motility, and differentiation. Integrins may protect cancer cells from an array of cytotoxic agents in several ways. This review will focus on the role of integrins in conferring resistance to tumor cells. We will discuss specific signal transduction pathways initiated by integrin ligation as a source of potential therapeutic targets for the fight against cancer.
Export Options
About this article
Cite this article as:
Ambriovic-Ristov Andreja and Osmak Maja, Integrin-Mediated Drug Resistance, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012048
DOI https://dx.doi.org/10.2174/157436206777012048 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Oleuropein Mediated Targeting of Signaling Network in Cancer
Current Topics in Medicinal Chemistry Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
Current Medicinal Chemistry Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples
Current Medical Imaging Emerging Insights in the Role of Tissue Factor in Cancer
Current Genomics Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry A New Approach for Skin-Derived Precursors to Ameliorate Skin Photodamage Through Activation of Nrf2 Signaling Pathway
Current Signal Transduction Therapy The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Therapeutic Potential of Group III Metabotropic Glutamate Receptors
Current Medicinal Chemistry